[go: up one dir, main page]

NO994146L - Celleoverflatemolekyl som formidler celleadhesjon og signatransmisjon - Google Patents

Celleoverflatemolekyl som formidler celleadhesjon og signatransmisjon

Info

Publication number
NO994146L
NO994146L NO994146A NO994146A NO994146L NO 994146 L NO994146 L NO 994146L NO 994146 A NO994146 A NO 994146A NO 994146 A NO994146 A NO 994146A NO 994146 L NO994146 L NO 994146L
Authority
NO
Norway
Prior art keywords
cell surface
surface molecule
surface molecules
cell
mediates
Prior art date
Application number
NO994146A
Other languages
English (en)
Other versions
NO327500B1 (no
NO994146D0 (no
Inventor
Takuya Tamatani
Katsunari Tezuka
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26403281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994146(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO994146D0 publication Critical patent/NO994146D0/no
Publication of NO994146L publication Critical patent/NO994146L/no
Publication of NO327500B1 publication Critical patent/NO327500B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Record Carriers (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19994146A 1997-02-27 1999-08-26 Polypeptid som utgjor et celleoverflatemolekyl, polypeptidfragment, gen, vektor, transformant, fusjonspolypeptid, homodimert molekyl, farmasoytisk preparat, antistoff, eller del av dette, hybridom, transgen mus samt knockout-mus. NO327500B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP6229097 1997-02-27
JP06221798A JP3521382B2 (ja) 1997-02-27 1998-02-26 細胞間接着及びシグナル伝達を媒介する細胞表面分子
PCT/JP1998/000837 WO1998038216A1 (fr) 1997-02-27 1998-02-27 Molecule de surface cellulaire induisant l'adhesion cellulaire et la transmission de signaux

Publications (3)

Publication Number Publication Date
NO994146D0 NO994146D0 (no) 1999-08-26
NO994146L true NO994146L (no) 1999-10-27
NO327500B1 NO327500B1 (no) 2009-07-20

Family

ID=26403281

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19994146A NO327500B1 (no) 1997-02-27 1999-08-26 Polypeptid som utgjor et celleoverflatemolekyl, polypeptidfragment, gen, vektor, transformant, fusjonspolypeptid, homodimert molekyl, farmasoytisk preparat, antistoff, eller del av dette, hybridom, transgen mus samt knockout-mus.
NO20073155A NO331064B1 (no) 1997-02-27 2007-06-20 Farmasoytisk preparat
NO20092369A NO20092369L (no) 1997-02-27 2009-06-18 Polypeptid som utgjor et celleoverflatemolekyl, polypeptidfragment, gen, vektor, transformant, fusjonspolypeptid, homodimert molekyl, farmasoytisk preparat, antistoff eller del av dette, hybridom og transgen mus

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20073155A NO331064B1 (no) 1997-02-27 2007-06-20 Farmasoytisk preparat
NO20092369A NO20092369L (no) 1997-02-27 2009-06-18 Polypeptid som utgjor et celleoverflatemolekyl, polypeptidfragment, gen, vektor, transformant, fusjonspolypeptid, homodimert molekyl, farmasoytisk preparat, antistoff eller del av dette, hybridom og transgen mus

Country Status (20)

Country Link
US (10) US7030225B1 (no)
EP (2) EP0984023B9 (no)
JP (1) JP3521382B2 (no)
KR (1) KR100349388B1 (no)
CN (3) CN100400546C (no)
AT (1) ATE360645T1 (no)
AU (1) AU732378B2 (no)
BR (1) BR9807788B1 (no)
CA (1) CA2282727C (no)
DE (1) DE69837658T2 (no)
DK (1) DK0984023T3 (no)
ES (1) ES2285763T3 (no)
HK (2) HK1026433A1 (no)
ID (1) ID23386A (no)
IL (3) IL131584A0 (no)
NO (3) NO327500B1 (no)
NZ (1) NZ337425A (no)
PT (1) PT984023E (no)
SI (1) SI0984023T1 (no)
WO (1) WO1998038216A1 (no)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
WO1999015553A2 (de) * 1997-09-23 1999-04-01 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
EP1119253A4 (en) * 1998-10-07 2005-12-21 Millennium Pharm Inc NEW SPECIFIC MOLECULES OF Th2 AND USES THEREOF
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
AU773954B2 (en) * 1999-02-03 2004-06-10 Amgen, Inc. Novel Polypeptides involved in immune response
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
WO2001008700A1 (en) 1999-07-28 2001-02-08 Genetics Institute, Inc. Preventing immune-mediated abortion by inhibiting costimulation
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
ES2290052T3 (es) 1999-09-21 2008-02-16 Genetics Institute, Llc Moleculas gl50 y usos para las mismas.
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
JP3543966B2 (ja) * 2000-05-18 2004-07-21 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
KR100895134B1 (ko) * 2000-05-26 2009-05-04 브리스톨-마이어스스퀴브컴파니 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도
AU2002308267A1 (en) * 2001-01-16 2002-10-03 Bayer Aktiengesellschaft Regulation of human icos v protein
NZ526507A (en) * 2001-01-26 2005-07-29 Commw Scient Ind Res Org Methods and means for producing efficient silencing construct using recombinational cloning
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
WO2002079499A1 (en) 2001-04-02 2002-10-10 Wyeth Pd-1, a receptor for b7-4, and uses therefor
JP2005505258A (ja) * 2001-06-21 2005-02-24 イシス・イノベイション・リミテッド アトピーにおけるａｎｇｅ遺伝子
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2005103086A1 (en) 2004-04-23 2005-11-03 Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2031062B1 (en) 2006-06-07 2018-10-24 The University of Tokyo Dna encoding polypeptide capable of modulating muscle-specific tyrosine kinase activity
WO2008149794A1 (ja) 2007-05-30 2008-12-11 Hoya Corporation 眼内レンズ挿入器具
WO2008149795A1 (ja) 2007-05-30 2008-12-11 Hoya Corporation 眼内レンズ挿入器具
EP2160796B1 (en) * 2007-06-22 2017-04-05 Nokia Technologies Oy An antenna arrangement
JP5086713B2 (ja) 2007-07-11 2012-11-28 Ｈｏｙａ株式会社 眼内レンズ挿入器具
EP2221065B1 (en) 2007-11-26 2016-12-28 Japan Science and Technology Agency Therapeutic or prophylactic agent, detection method and detection agent for metabolic syndrome, and method for screening of candidate compound for therapeutic agent for metabolic syndrome
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
EP2455396A4 (en) 2009-07-16 2013-05-01 Otsuka Chemical Co Ltd EXTRACELLULAR AILIM DOMAIN PLACED WITH SUGAR CHAINS AND METHOD OF MANUFACTURING THE SAME
US20130042873A1 (en) 2010-03-09 2013-02-21 Klaus Bechgaard Contraceptive device
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
PL2925350T3 (pl) 2012-12-03 2019-07-31 Bristol-Myers Squibb Company Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
ITUB20151014A1 (it) * 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
WO2017190100A1 (en) * 2016-04-28 2017-11-02 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
WO2018043707A1 (ja) 2016-09-02 2018-03-08 学校法人慶應義塾 視覚機能再生剤又は視覚機能低下予防剤
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
EP3976831A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
US11771741B2 (en) 2019-09-13 2023-10-03 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
JPWO2021049634A1 (no) 2019-09-13 2021-03-18
KR20220088752A (ko) 2019-10-28 2022-06-28 메드임뮨 리미티드 흉선 기질 림포포이에틴 (tslp)-결합 항체들의 건조 분말 제형 및 이의 사용 방법
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
CA3182445A1 (en) 2020-06-11 2021-12-16 Francisco Leon Methods and compositions for preventing type 1 diabetes
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
EP4215212A4 (en) 2020-09-17 2024-04-24 Restore Vision Inc. COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH ENDOPLASTIC RETICULUM STRESS OR ALL-TRANS-RETINOAL
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
JP2024503265A (ja) 2020-12-28 2024-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗体組成物およびその使用の方法
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US182667A (en) * 1876-09-26 Improvement in flue-stoppers
US177191A (en) * 1876-05-09 Improvement in lamps
US164697A (en) * 1875-06-22 Improvement in cloth-steaming machines
NZ218336A (en) * 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
SE8801537D0 (sv) * 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5580756A (en) 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5504126A (en) * 1991-11-07 1996-04-02 Safas Corporation Mineral-like coating and methods of using same
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5914112A (en) 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
ATE222774T1 (de) 1996-01-23 2002-09-15 Genentech Inc Antikörper gegen cd 18 zur verwendung gegen gehirnschlag
PT928197E (pt) 1996-09-18 2003-06-30 Zetesis Spa Utilizacao de proteinas como agentes contra doencas de natureza autoimunitaria
KR100510604B1 (ko) 1996-11-08 2005-08-31 아이덱 파마슈티칼즈 코포레이션 특정 항체와 사람 ｂ7.1 및 ｂ7.2의 공동 자극 항원간의 특이한 결합 상호작용의 확인 방법
AU4145597A (en) 1997-02-20 1998-09-09 Cedars-Sinai Medical Center Ulcerative colitis panca secretory vesicle antigen and methods of using sa me
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
WO2001032675A1 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 32 human secreted proteins
DK0973804T3 (da) 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF-antistoffer
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
WO1999015553A2 (de) * 1997-09-23 1999-04-01 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
JPH11228442A (ja) 1998-02-09 1999-08-24 Cypros Pharmaceut Corp 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用
JP2000154151A (ja) 1998-09-14 2000-06-06 Kyo Jo 免疫抑制剤
EP1119253A4 (en) 1998-10-07 2005-12-21 Millennium Pharm Inc NEW SPECIFIC MOLECULES OF Th2 AND USES THEREOF
AU773954B2 (en) 1999-02-03 2004-06-10 Amgen, Inc. Novel Polypeptides involved in immune response
BR0010711A (pt) 1999-05-06 2002-02-13 Genetics Inst Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
WO2001008700A1 (en) 1999-07-28 2001-02-08 Genetics Institute, Inc. Preventing immune-mediated abortion by inhibiting costimulation
WO2001012658A2 (en) 1999-08-11 2001-02-22 Isis Innovations Limited Human icos ligand and application thereof
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
CA2383800A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences Inc. 52 human secreted proteins
ES2290052T3 (es) 1999-09-21 2008-02-16 Genetics Institute, Llc Moleculas gl50 y usos para las mismas.
WO2001064704A1 (en) 2000-03-02 2001-09-07 Mayo Foundation For Medical Education And Research hB7-H2, A NOVEL CO-STIMULATORY MOLECULE
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
EP2351840A1 (en) 2000-11-28 2011-08-03 Amgen Inc. Polypeptides involved in immune response
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20040001831A1 (en) * 2002-06-26 2004-01-01 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders

Also Published As

Publication number Publication date
US20080248031A1 (en) 2008-10-09
KR100349388B1 (ko) 2002-08-22
IL131584A (en) 2010-06-30
US7279560B2 (en) 2007-10-09
US20040151720A1 (en) 2004-08-05
BR9807788B1 (pt) 2010-11-16
NO327500B1 (no) 2009-07-20
CN1293190C (zh) 2007-01-03
ATE360645T1 (de) 2007-05-15
US20040146506A1 (en) 2004-07-29
NZ337425A (en) 2001-04-27
EP0984023A1 (en) 2000-03-08
CN1221569C (zh) 2005-10-05
JPH1129599A (ja) 1999-02-02
JP3521382B2 (ja) 2004-04-19
EP0984023A4 (en) 2001-10-31
EP1502920A3 (en) 2005-02-09
EP1502920A2 (en) 2005-02-02
AU6118598A (en) 1998-09-18
US20040073012A1 (en) 2004-04-15
CA2282727A1 (en) 1998-09-03
PT984023E (pt) 2007-07-19
US7294473B2 (en) 2007-11-13
NO20092369L (no) 1999-10-27
IL131584A0 (en) 2001-01-28
CN1253567A (zh) 2000-05-17
US7259147B2 (en) 2007-08-21
US7196175B2 (en) 2007-03-27
DK0984023T3 (da) 2007-07-09
US20040229788A1 (en) 2004-11-18
EP0984023B1 (en) 2007-04-25
AU732378B2 (en) 2001-04-26
NO994146D0 (no) 1999-08-26
US8389690B2 (en) 2013-03-05
HK1079240A1 (en) 2006-03-31
US20030083472A1 (en) 2003-05-01
ES2285763T3 (es) 2007-11-16
ID23386A (id) 2000-04-20
CN1624115A (zh) 2005-06-08
IL206603A0 (en) 2011-07-31
US7030225B1 (en) 2006-04-18
EP0984023B9 (en) 2008-04-16
NO331064B1 (no) 2011-09-26
SI0984023T1 (sl) 2007-08-31
CN100400546C (zh) 2008-07-09
DE69837658D1 (de) 2007-06-06
US7932358B2 (en) 2011-04-26
NO20073155L (no) 1999-10-27
US20040120945A1 (en) 2004-06-24
KR20000075761A (ko) 2000-12-26
US20040151669A1 (en) 2004-08-05
WO1998038216A1 (fr) 1998-09-03
EP1502920B1 (en) 2015-09-09
HK1026433A1 (en) 2000-12-15
US7247612B2 (en) 2007-07-24
DE69837658T2 (de) 2007-12-27
CN1618811A (zh) 2005-05-25
US20120003231A1 (en) 2012-01-05
CA2282727C (en) 2009-06-16
BR9807788A (pt) 2000-02-15

Similar Documents

Publication Publication Date Title
NO994146L (no) Celleoverflatemolekyl som formidler celleadhesjon og signatransmisjon
BR9710968A (pt) Antìgenos de célula b humana; reagentes correlatos
DE69841102D1 (de) Monoklonaler antikörper gegen ein prion protein und dessen verwendung zum nachweis von prionen
DK0749325T3 (da) Bispecifikke molekyler med klinisk anvendelse
DE59608103D1 (de) Sortiervorrichtung für biologische Zellen oder Viren
DE69534235D1 (de) Cytokin lerk-7
DE59508908D1 (de) Elektrochemischer Enzymbiosensor
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
AU5665696A (en) Novel methods for the assay of troponin i and t and complexe s of troponin i and t and selection of antibodies for use in immunoassays
DE59609222D1 (de) Amperometrischer Biosensor
DE69021456D1 (de) Monoklonale Antikörper gegen aktivierte endotheliale Zellen.
FI960469A0 (fi) DNA:ta sekvenssoivia entsyymejä
EP0206302A3 (en) New assay and purification of amyloid components, applications, and kits therefor
WO2001016184A3 (en) Diagnostic assay for type 2 heparin-induced thrombocytopenia
ATE205600T1 (de) Leukozytadhaesiontest
ATE154395T1 (de) Monoklonale antikörper
ITTO940399A0 (it) Saggio immunologico per analiti in campioni, che utilizza agenti alchilanti.
WO2005062959A3 (en) Isolated t lymphocyte receptors specific for human autoantigens complexed with human mhc molecules and methods of making and using same
ATE215564T1 (de) Nm03, ein monoklonaler antikörper gegen das hiv-1 gp120 protein
NO20000079D0 (no) Ancrod spesifikke monoklonale antistoff, antistoff- fragmenter, blandinger, derivater og anvendelse derav
SE9502764D0 (sv) Analytical assay
KR970014497U (ko) 방풍판이 부착된 휴대용 가스렌지
KR970038667U (ko) 내구력이 향상된 러버행거구조
KR970038668U (ko) 내구력이 향상된 러버행거구조
IT9006603A1 (it) Test immunoenzimatico classe specifico per la ricerca e determinazione degli anticorpi anti-cardiolipina nel siero.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees